Pluri Inc. PLUR
leveraging our proprietary cell expansion platform to develop scalable, cell-based solutions across the healthcare, food, and agriculture
sectors. Through a collaborative network of ventures, we are advancing a diverse pipeline of products and services, including cultivated
food, regenerative medicine, and cell-based ingredients. We have developed a unique three-dimensional ("3D") technology platform
for cell expansion with an industrial-scale cell manufacturing facility operated in accordance with Good Manufacturing Practice ("GMP")
Last close
0.99
2026-10-23
Market cap
$10.7M
2026-03-31 share count
52-week range
0.85 - 4.87
Valuation FY2025 figures against the last close
P/S8.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.56
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $326.0K | $287.0K | $234.0K | — | $23.0K | $54.0K | $50.0K | — | $2.8M |
| Cost of revenue | $682.0K | $4.0K | $9.0K | — | — | — | $2.0K | $2.0K | — | $100.0K |
| Gross profit | $654.0K | $322.0K | $278.0K | $234.0K | — | $23.0K | $52.0K | $48.0K | — | $2.7M |
| R&D | $12.9M | $12.4M | $15.7M | $24.6M | $30.5M | $23.1M | $29.9M | $26.4M | $24.0M | $22.9M |
| SG&A | $10.0M | $10.0M | $11.8M | $17.4M | $20.6M | $7.9M | $9.2M | $11.2M | $6.9M | $6.5M |
| Operating income | -$22.2M | -$22.2M | -$27.2M | -$41.6M | -$50.6M | -$29.5M | -$35.5M | -$33.7M | -$28.0M | -$23.3M |
| Interest expense | $873.0K | $866.0K | $843.0K | $887.0K | $78.0K | — | — | — | — | — |
| Pre-tax income | -$23.3M | -$21.3M | — | — | — | — | — | — | — | — |
| Income tax | $5.0K | — | — | — | — | — | — | — | — | — |
| Net income | $23.2M | $21.3M | $28.9M | -$41.2M | -$49.9M | -$29.2M | -$35.3M | -$26.1M | -$27.8M | -$23.2M |
| EPS, basic | -3.56 | -3.99 | -6.24 | -1.28 | -1.77 | — | — | — | — | — |
| EPS, diluted | -3.56 | -3.99 | -6.24 | -1.28 | -1.77 | -1.60 | -2.90 | -2.50 | -3.20 | -0.29 |
| Shares, diluted (wtd. avg.) | 6.3M | 5.2M | 4.6M | 32.2M | 28.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.9M | $6.8M | $6.3M | $11.4M | $31.8M | $9.2M | $5.2M | $9.9M | $5.7M | $7.1M |
| Short-term investments | — | — | — | — | $33.7M | $37.5M | $19.6M | $21.1M | $6.2M | $8.6M |
| Receivables | — | — | — | $3.0K | $19.0K | — | — | $58.0K | $1.0M | $2.2M |
| Total current assets | $22.1M | $31.1M | $41.4M | $57.7M | $67.4M | $48.5M | $26.4M | $32.0M | $29.0M | $35.6M |
| Property, plant and equipment | $1.8M | $688.0K | $688.0K | $739.0K | $1.5M | $2.5M | $3.8M | $5.7M | $7.3M | $9.2M |
| Goodwill | $3.1M | — | — | — | — | — | — | — | — | — |
| Other intangibles | $2.8M | — | — | — | — | — | — | — | — | — |
| Total assets | $38.7M | $39.5M | $50.8M | $68.1M | $93.5M | $65.5M | $31.3M | $39.0M | $37.5M | $45.9M |
| Accounts payable | — | — | — | — | — | $2.0M | $2.3M | $3.3M | $2.0M | $2.7M |
| Total current liabilities | $32.3M | $4.5M | $5.6M | $6.8M | $11.5M | $8.0M | $8.2M | $8.5M | $5.4M | $5.8M |
| Retained earnings | -$443.1M | -$420.5M | -$399.6M | -$371.3M | -$330.0M | -$280.2M | -$251.0M | -$215.7M | -$189.6M | -$161.8M |
| Total equity | -$6.8M | $96.0K | $15.3M | $32.2M | $57.2M | $56.1M | $21.8M | $28.5M | $30.3M | $38.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.2M | -$18.0M | -$22.9M | -$36.5M | -$30.9M | -$26.4M | -$29.5M | -$21.4M | -$21.6M | -$18.5M |
| Depreciation and amortisation | $286.0K | $253.0K | $362.0K | $1.1M | $1.4M | $1.6M | $2.0M | $2.0M | $2.2M | $2.1M |
| Stock-based compensation | $2.1M | $2.6M | $4.0M | $8.9M | $14.0M | $2.6M | $5.1M | $6.5M | $3.7M | $3.1M |
| Capital expenditure | $1.6M | $323.0K | $262.0K | $280.0K | $373.0K | $270.0K | $239.0K | $342.0K | $378.0K | $1.8M |
| Investing cash flow | $8.0M | $10.6M | $9.7M | $11.8M | -$7.3M | -$30.5M | $1.2M | $5.7M | $4.4M | $1.3M |
| Financing cash flow | $9.5M | $8.8M | $8.0M | $7.5M | $61.4M | $60.9M | $23.6M | $19.9M | $15.8M | $807.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-047070.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | — | $50.0K | $54.0K | $23.0K | — | $234.0K | $287.0K | $326.0K | $1.3M |
| Gross profit | $2.7M | — | $48.0K | $52.0K | $23.0K | — | $234.0K | $278.0K | $322.0K | $654.0K |
| Net income | -$23.2M | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.2M | $28.9M | $21.3M | $23.2M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |